A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer-Reference-Cited by-同舟云学术

A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer

Published:2016-11-30 Issue:6 Volume:232 Page:1571-1578
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J. Cell. Physiol.

Author:

Gamucci Teresa¹,Mentuccia Lucia¹,Natoli Clara²,Sperduti Isabella³,Cassano Alessandra⁴,Michelotti Andrea⁵,Di Lauro Luigi⁶,Sergi Domenico⁶,Fabi Alessandra⁷,Sarobba Maria G.⁸,Marchetti Paolo⁹,Barba Maddalena⁶¹⁰,Magnolfi Emanuela¹,Maugeri-Saccà Marcello⁶¹⁰,Rossi Ernesto⁴,Sini Valentina⁹,Grassadonia Antonino²,Pellegrini Domenica⁷,Astone Antonino⁴,Nisticò Cecilia⁷,Angelini Franco¹¹,Vaccaro Angela¹,Pellegrino Arianna¹²,De Angelis Claudia⁵,Palleschi Michela¹³,Moscetti Luca¹⁴¹⁵,Bertolini Ilaria⁵,Buglioni Simonetta¹⁶,Giordano Antonio¹⁷,Pizzuti Laura⁶,Vici Patrizia⁶

Affiliation:

1. Medical Oncology Unit; Frosinone Italy

2. Department of Medical, Oral and Biotechnological Sciences; Centro Scienze dell’ Invecchiamento e Medicina Traslazionale - CeSI-MeT; Chieti Italy

3. Bio-Statistics Unit, Regina Elena National Cancer Institute; Rome Italy

4. Department of Medical Oncology; Policlinico Universitario A. Gemelli; Rome Italy

5. Oncology Unit I; Azienda Ospedaliera Universitaria Pisana; Pisa Italy

6. Division of Medical Oncology 2; Regina Elena National Cancer Institute; Rome Italy

7. Division of Medical Oncology 1; Regina Elena National Cancer Institute; Rome Italy

8. Medical Oncology Unit; Nuoro Italy

9. Department of Clinical and Molecular Medicine; “Sapienza” University of Rome; Azienda Ospedaliera Sant'Andrea; Rome Italy

10. Scientific Direction; Regina Elena National Cancer Institute; Rome Italy

11. Medical Oncology Unit; Regina Apostolorum Hospital; Albano, Rome Italy

12. Medical Oncology Unit, Ospedale San Pietro Fatebenefratelli; Rome Italy

13. Medical Oncology Unit, Policlinico Umberto I; Rome Italy

14. Medical Oncology Unit, Belcolle Hospital; Viterbo; Italy

15. Department of Medical and Surgical Sciences for Children and Adults; Azienda Ospedaliero-Universitaria Policlinico di Modena; Modena Italy

16. Department of Pathology; Regina Elena National Cancer Institute; Rome Italy

17. Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology; College of Science and Technology; Temple University; Philadelphia Pennsylvania

Funder

Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO)

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcp.25685/fullpdf

Reference36 articles.

1. Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo;Banerjee;Clin Cancer Res,2010

2. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial;Bennouna;Lancet Oncol,2013

3. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients;Bottini;J Clin Oncol,2006